RestoreVision

Raised $8.2M in a Pre-Series B round, announced 15 April 2026.

Total raised: $8.2M

Latest round Pre-Series BCountry JapanSector Health

Round

$8.2MPre-Series B, 15 April 2026

Pre-Series B via J-KISS to advance RV-001 for retinitis pigmentosa globally.

Amount: $8.2M
Stage: Pre-Series B
Announced: 15 April 2026
Lead: Astellas Venture Management
Other investors: Ajinomoto, Shionogi, Japan Venture Capital, JIC Venture Growth Investments, Kyoto University Innovation Capital
Use of funds: Pre-Series B via J-KISS to advance RV-001 for retinitis pigmentosa globally.
Checked: Amount and date checked against the press source
Source: RestoreVision raises ¥1.3B pre-Series B for retinal gene therapy thebridge.jp

Company

Optogenetic gene therapy to restore vision in retinal disease

Based in: Tokyo, Japan
Sector: Health

Questions

How much has RestoreVision raised?

RestoreVision raised $8.2M in a Pre-Series B round, announced on 15 April 2026.

Who invested in RestoreVision?

Astellas Venture Management led. Investors include Astellas Venture Management, Ajinomoto, Shionogi, Japan Venture Capital, JIC Venture Growth Investments and Kyoto University Innovation Capital.